Has Anthony Santoro, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,675 in general payments to Anthony Santoro, MD across 346 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Anthony Santoro, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Anthony Santoro, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Anthony Santoro, MD

Procedural Dermatology · Doylestown, PANPI 1164454237

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.6% of the total across 346 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by Johnson & Johnson at 29.3% of the total.

$7,675in general payments, 2019–2025

Across 346 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$2K
Regeneron Healthcare Solutions, Inc.$1K
AbbVie$650
Janssen Scientific Affairs, LLC$598
Amgen$514
Helsinn Therapeutics (U.S.), Inc.$482
plus $2K from 25 others

What the payments were for

Food & beverage$7,57099%
Education$1051%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson(2 entities)	120	$2,252
Regeneron Healthcare Solutions, Inc.	32	$1,012
AbbVie	40	$650
Janssen Scientific Affairs, LLC	5	$598
Amgen	14	$514
Helsinn Therapeutics (U.S.), Inc.	28	$482
E.r. Squibb & Sons, L.L.C.	13	$253
Sun Pharmaceutical Industries Inc.	15	$246
Galderma Laboratories, L.p.	12	$175
Lilly USA, LLC	8	$152
Arcutis Biotherapeutics, Inc.	7	$143
Incyte Corporation	7	$143
Organon	2	$133
EPI Health, LLC	4	$117
UCB, Inc.	5	$107
LEO Pharma Inc.	6	$103
Almirall LLC	4	$83
Novartis	4	$78
Botanix SB Inc	2	$56
Lifenet Health	1	$47
Integra Lifesciences Corporation	1	$44
Genentech USA, Inc.	3	$43
Boehringer Ingelheim	2	$40
Sanofi	2	$37
Merck	2	$37
Kerecis Limited	1	$33
DUSA Pharmaceuticals, Inc.	2	$31
Blueprint Medicines Corporation	1	$21
Mayne Pharma Commercial LLC	1	$20
Sandoz	1	$14
Prugen, Inc. Pharmaceuticals	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Tremfya$979
Otezla$270
VTAMA$126
DUPIXENT$124
Rinvoq$113

How this compares

$7,675 in reported general payments places this provider in the 85th percentile of 26 procedural dermatology providers in Pennsylvania.

See all procedural dermatology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$292,730

Medicare patients

1,236

Services billed

6,749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Fluorouracil	84	$4,634
Pimecrolimus	11	$4,321
Ketoconazole	82	$1,829
Metronidazole	25	$1,580
Triamcinolone Acetonide	108	$1,404
Doxycycline Hyclate	48	$1,123
Hydrocortisone	117	$921
Clobetasol Propionate	23	$919
Betamethasone Dipropionate	17	$523
Fluocinonide	17	$330
Prednisone	14	$35

Paid to pharmacies, not to this prescriber.

Other procedural dermatology in Doylestown

Jonathan WolfePlymouth Meeting$252K
Stuart GlasserGreensburg$13K
Danielle DehoratiusBryn Mawr$12K
Barbara MathesPhiladelphia$7K
Vincent HerbstWilliamsport$4K
Elizabeth AndersonCamp Hill$3K
John BartonEnola$2K
Anne AngelesPhiladelphia$2K
Louis BrownPhiladelphia$1K
Carol NeishPittsburgh$518

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →